Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib — 12; 8 milligram (mg)
Phase 2 N=99 Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
Neuromuscular Blockade
Primary: Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9 — 52.05; 22.73; 4.93; 6.25 minutes
Phase 2 N=60 Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
Phase 2 N=39 Sunitinib in Refractory Adrenocortical Carcinoma
Adrenocortical Carcinoma
Primary: Assessment of Clinical Benefit Due to Treatment With Sunitinib — 5 Participants
Phase 2 N=50 Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
Neuromuscular Blockade
Primary: Time From Start of Administration of MK-8616 to Recovery T4/T1 Ratio to 0.9 — 44.18; 19.08; 5.38; 3.32 Minutes
Phase 2 N=152 A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
Neuralgia, Postherpetic
Primary: Percentage Change in Average Pain Intensity Score From Baseline to the Last Week of the 4-week Treatment Period — -26.16; -26.11; -27.36 percentage of change — p==0.965
Phase 2 N=125 Trial of Ibudilast for Methamphetamine Dependence
Methamphetamine Dependence · HIV Infection
Primary: Methamphetamine Use — 9; 10 Participants
Phase 2 N=43 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Phase 2 N=26 Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Functional Beta Cell Mass — 0.74; 0.46 nmol/L
Phase 2 N=30 Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Molluscum Contagiosum
Primary: Number of Participants With Total Lesion Clearance — 11 Participants
Phase 2 N=170 A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
Schizophrenia
Primary: Visual Memory — 37.1; 33.9; 39.6; 34.2 visual memory scores
Phase 2 N=122 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
Influenza · Multiple Myeloma · Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Treatment Failure by Primary Endpoint — 26; 13 Participants
Phase 2 N=22 Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 28.5; 7.5 events/hours of sleep — p=<0.001
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants